|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG004944046 |
003 |
DE-627 |
005 |
20230629100631.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2023 xx |||||o 00| ||eng c |
035 |
|
|
|a (DE-627)CTG004944046
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2014-001589-85-GB
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)D081FC00001
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
245 |
1 |
0 |
|a Olaparib in gBRCA Mutated Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
|b A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy - POLO
|
264 |
|
1 |
|c 2023
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 21-07-2014, Last updated: 2023-06-29
|
650 |
|
4 |
|a Medical Condition: Patients with gBRCA mutated metastatic pancreatic cancer whose disease has not progressed onfirst line platinum based chemotherapy;Therapeutic area: Diseases [C] - Cancer [C04]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Phase: Phase 3
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 21. Juni
|
773 |
1 |
8 |
|g year:2023
|g day:21
|g month:06
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001589-85
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2023
|b 21
|c 06
|